Találati lista | Tudóstér

001-es BibID:	BIBFORM093765
035-os BibID:	(WoS)000512990500007 (Scopus)85078431398
Első szerző:	Chichareon, Ply
Cím:	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention : pre-specified subgroup analysis from the randomized GLOBAL LEADERS study / Ply Chichareon, Rodrigo Modolo, Norihiro Kogame, Kuniaki Takahashi, Chun-Chin Chang, Mariusz Tomaniak, Roberto Botelho, Eric Eeckhout, Sjoerd Hofma, Diana Trendafilova-Lazarova, Zsolt Kőszegi, Andres Iñiguez, Joanna J. Wykrzykowska, Jan J. Piek, Scot Garg, Christian Hamm, Philippe Gabriel Steg, Peter Jüni, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys
Dátum:	2020
ISSN:	0021-9150
Megjegyzések:	Background and aims: Diabetes has been well recognized as a strong predictor for adverse outcomes after percutaneous coronary intervention (PCI), however, studies in the era of drug-eluting stent and potent P2Y12 inhibitors have shown conflicting results. We aimed to assess ischemic and bleeding outcomes after contemporary PCI according to diabetic status. Methods: We studied 15,957 patients undergoing PCI for stable or acute coronary syndrome in the GLOBAL LEADERS study with known baseline diabetic status. The primary endpoint was all-cause death or new Q-wave myocardial infarction at 2 years. The secondary safety endpoint was major bleeding defined as bleeding academic research consortium (BARC) type 3 or 5. Results: A quarter of the study cohort were diabetic (4038/15,957), and these patients had a significantly higher risk of primary endpoint at 2 years compared to non-diabetics (adjusted hazard ratio [HR] 1.38; 95% confidence interval [CI] 1.17-1.63). The difference was driven by a significantly higher risk of all-cause mortality at 2 years in diabetics (adjusted HR 1.47, 95% CI 1.22-1.78). The risk of BARC 3 or 5 bleeding was comparable between the two groups (adjusted HR 1.09, 95% CI 0.86-1.39). The antiplatelet strategy (experimental versus reference strategy) had no significant effect on the rates of primary endpoint and secondary safety endpoint at 2 years in patients with and without diabetes. Conclusions: Diabetic patients had higher risk of ischemic events after PCI than non-diabetic patients, whilst bleeding risk was comparable. The outcomes of diabetic patients following PCI were not affected by the two different antiplatelet strategies.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Coronary artery disease Diabetes Percutaneous coronary intervention Ticagrelor
Megjelenés:	Atherosclerosis. - 295 (2020), p. 45-53. -
További szerzők:	Modolo, Rodrigo Kogame, Norihiro Takahashi, Kuniaki Chang, Chun-Chin Tomaniak, Mariusz Botelho, Roberto Eeckhout, Eric Hofma, Sjoerd Trendafilova-Lazarova, Diana Kőszegi Zsolt (1962-) (kardiológus, belgyógyász) Iñiguez, Andres Wykrzykowska, Joanna J. Piek, Jan J. Garg, Scot Hamm, Christian Steg, Philippe Gabriel Jüni, Peter Vranckx, Pascal Valgimigli, Marco Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM111141
035-os BibID:	(cikkazonosító)e024291 (scopus)85130643091 (wos)000796637400002
Első szerző:	Gragnano, Felice
Cím:	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation : Per-Protocol Analysis of the GLOBAL LEADERS Trial / Gragnano Felice, Zwahlen Marcel, Vranckx Pascal, Heg Dik, Schmidlin Kurt, Hamm Christian, Steg Philippe Gabriel, Gargiulo Giuseppe, McFadden Eugene P., Onuma Yoshinobu, Chichareon Ply, Benit Edouard, Möllmann Helge, Janssens Luc, Leonardi Sergio, Zurakowski Aleksander, Arrivi Alessio, Van Geuns Robert Jan, Huber Kurt, Slagboom Ton, Calabro Paolo, Serruys Patrick W., Jüni Peter, Valgimigli Marco, Windecker Stephan, GLOBAL LEADERS Investigators
Dátum:	2022
ISSN:	2047-9980
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Journal of the American Heart Association. - 11 : 10 (2022), p. 1-12. -
További szerzők:	Zwahlen, Marcel Vranckx, Pascal Heg, Dik Schmidlin, Kurt Hamm, Christian Steg, Philippe Gabriel Gargiulo, Giuseppe McFadden, Eugene P. Onuma, Yoshinobu Chichareon, Ply Benit, Edouard Möllmann, Helge Janssens, Luc Leonardi, Sergio Zurakowski, Aleksander Arrivi, Alessio Van Geuns, Robert Jan Huber, Kurt Slagboom, Ton Calabrò, Paolo Serruys, Patrick W. Jüni, Peter Valgimigli, Marco Windecker, Stephan Kőszegi Zsolt (1962-) (kardiológus, belgyógyász) GLOBAL LEADERS Investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM082818
035-os BibID:	(PMID)31475795
Első szerző:	Mehta, Shamir
Cím:	Complete Revascularization with Multivessel PCI for Myocardial Infarction / Shamir R. Mehta, David A. Wood, Robert F. Storey, Roxana Mehran, Kevin R. Bainey, Helen Nguyen, Brandi Meeks, Giuseppe Di Pasquale, Jose López-Sendón, David P. Faxon, Laura Mauri, Sunil V. Rao, Laurent Feldman, P. Gabriel Steg, Álvaro Avezum, Tej Sheth, Natalia Pinilla-Echeverri, Raul Moreno, Gianluca Campo, Benjamin Wrigley, Sasko Kedev, Andrew Sutton, Richard Oliver, Josep Rodés-Cabau, Goran Stanković, Robert Welsh, Shahar Lavi, Warren J. Cantor, Jia Wang, Juliet Nakamya, Shrikant I. Bangdiwala, John A. Cairns, COMPLETE Trial Steering Committee and Investigators
Dátum:	2019
ISSN:	0028-4793
Megjegyzések:	In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear. METHODS: We randomly assigned patients with STEMI and multivessel coronary artery disease who had undergone successful culprit-lesion PCI to a strategy of either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization. Randomization was stratified according to the intended timing of nonculprit-lesion PCI (either during or after the index hospitalization). The first coprimary outcome was the composite of cardiovascular death or myocardial infarction; the second coprimary outcome was the composite of cardiovascular death, myocardial infarction, or ischemia-driven revascularization. RESULTS: At a median follow-up of 3 years, the first coprimary outcome had occurred in 158 of the 2016 patients (7.8%) in the complete-revascularization group as compared with 213 of the 2025 patients (10.5%) in the culprit-lesion-only PCI group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.91; P?=?0.004). The second coprimary outcome had occurred in 179 patients (8.9%) in the complete-revascularization group as compared with 339 patients (16.7%) in the culprit-lesion-only PCI group (hazard ratio, 0.51; 95% CI, 0.43 to 0.61; P<0.001). For both coprimary outcomes, the benefit of complete revascularization was consistently observed regardless of the intended timing of nonculprit-lesion PCI (P?=?0.62 and P?=?0.27 for interaction for the first and second coprimary outcomes, respectively). CONCLUSIONS: Among patients with STEMI and multivessel coronary artery disease, complete revascularization was superior to culprit-lesion-only PCI in reducing the risk of cardiovascular death or myocardial infarction, as well as the risk of cardiovascular death, myocardial infarction, or ischemia-driven revascularization. (Funded by the Canadian Institutes of Health Research and others; COMPLETE ClinicalTrials.gov number, NCT01740479.).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	New England Journal of Medicine. - 381 : 15 (2019), p. 1411-1421. -
További szerzők:	Wood, David A. Storey, Robert F. Mehran, Roxana Bainey, Kevin R. Nguyen, Helen Meeks, Brandi Di Pasquale, Giuseppe Lopez-Sendon, Jose Faxon, David P. Mauri, Laura Rao, Sunil V. Feldman, Laurent Steg, Philippe Gabriel Avezum, Álvaro Sheth, Tej Pinilla-Echeverri, Natalia Moreno, Raul Campo, Gianluca Wrigley, Benjamin Kedev, Sasko Sutton, Andrew Oliver, Richard Rodés-Cabau, Josep Stanković, Goran Welsh, Robert Lavi, Shahar Cantor, Warren J. Wang, Jia-Ning Nakamya, Juliet Bangdiwala, Shrikant I. Cairns, John A. Kőszegi Zsolt (1962-) (kardiológus, belgyógyász) COMPLETE Trial Steering Committee and Investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: